Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 14;10:6323. doi: 10.1038/s41598-020-62953-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

p21^WAF1 activation in Snol-A treated p53-deficient cells was mediated by suppression of CARF. (A) Immunoblot showing decrease in CARF protein in Snin-I and Snol-A (10 μM) treated SKOV-3; Quantitation of CARF levels is shown below. (B) Immunostaining showing decrease in CARF and increase in p21^WAF1 expression levels in Snol-A, but not Snin-1, treated SKOV-3 cells; quantitation of the fluorescent intensities is shown on the right. (C,D) Immunoblots showing expression levels of CARF and p21^WAF1 in Snol-A treated (24 and 48 h) SKOV-3 cells. Snol-A caused suppression of CARF and upregulation of p21^WAF1 in a dose- and time-depended manner. Quantitation of proteins in control and treated cells is shown below. (E) Immunoblots of CARF and p21^WAF1 in Snol-A treated (48 h) Saos-2 showing low CARF and high p21^WAF1 levels in treated cells. Quantitation of their levels is shown at the bottom.